Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack survivors: could a dual ablation approach stop deadly rhythms?

NCT ID NCT07240441

Disease control Sponsor: MEDICOVER SP Z O.O. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests two ways to treat ventricular tachycardia (a fast, dangerous heart rhythm) in people who have had a heart attack and have an implanted defibrillator. One method uses standard ablation inside the heart; the other also ablates outside the heart. The study will track deaths, electrical storms, and defibrillator shocks over two years to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation (heart procedure)
What this could lead to
If successful, this could show that a more extensive ablation approach (inside and outside the heart) is better at preventing dangerous heart rhythms and shocks from an implanted defibrillator.
What could go wrong
This is a mid-sized trial, not yet proven. The more extensive procedure carries extra risks like bleeding around the heart. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Status after myocardial infarction (minimum 3 months before inclusion in the study). * Documented post-infarction VT or VF. * Implantable ICD (at least 2 weeks before ablation) or CRT-D (at least 2 months before ablation). * A history of at least one from below: 1. One or more high energy interventions. 2. Three or more adequate antitachycardia pacing therapies, including one symptomatic. 3. Three or more episodes of VT in 24 hours (interrupted by ATP or shock) - electrical storm. 4. Sustained VT recorded on ECG with a cycle length longer than the ICD detection threshold. * Age between 18 and 85 years. * Signed informed consent to participate in the study. Exclusion Criteria: * Obesity with BMI \> 40 kg/m2. * Left ventricle ejection fraction \< 20%. * Pregnancy or breastfeeding. * Renal failure (eGFR \< 20 mL/min/1.73m2). * Fresh ballot thrombus in the left ventricle. * Suspicion of massive adhesions in the pericardium that may impede pericardial puncture. * Ablation of the post-infarction VT in the left ventricle in medical history. * Previous heart surgery. * Acute conditions that prevent ablation (including active infection, overt hyperthyroidism and others listed below). * Active neoplastic disease. * Heart failure with NYHA IV. * Life expectancy less than 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ablation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ablation Implantable cardiac defibrillator Myocardial infarction (MI) Ventricular tachycardias

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grochowski Hospital named after Dr. Rafał Masztak, MD

    NOT_YET_RECRUITING

    Warsaw, Poland

  • Independent Public Health Care Facility University Hospital in Krakow

    NOT_YET_RECRUITING

    Krakow, Poland

  • Medical University of Warsaw

    RECRUITING

    Warsaw, Masovian Voivodeship, Poland

  • Medicover Hospital

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-972, Poland

  • National Institute of Cardiology

    NOT_YET_RECRUITING

    Warsaw, Masovian Voivodeship, Poland

  • University Clinical Center based in Gdańsk

    NOT_YET_RECRUITING

    Gdansk, Poland

  • University Clinical Hospital No. 2 PUM in Szczecin

    NOT_YET_RECRUITING

    Szczecin, Poland

  • University Clinical Hospital in Poznań

    NOT_YET_RECRUITING

    Poznan, Poland

  • University Hospital No. 1 in Bydgoszcz

    NOT_YET_RECRUITING

    Bydgoszcz, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.